Discordance between patient and physician global assessment scores is common in SSc, with each incorporating different factors when assessing.
The FDA has granted Fast Track designation to BM-3103, a novel topical mTOR inhibitor for epidermolysis bullosa simplex currently in phase 2.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results